• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medical and Pediatric Oncology: The Official Journal of the American Association for Cancer Education >A discourse: the 2002 Wataru W. Sutow lecture. Hodgkin disease in children--perspectives and progress.
【24h】

A discourse: the 2002 Wataru W. Sutow lecture. Hodgkin disease in children--perspectives and progress.

机译：话语：2002年Wataru W. Sutow演讲。儿童霍奇金病-观点和进展。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

THE PIONEER: Wataru W. Sutow, 1912-1981, was a remarkable and pivotal leader in pediatric oncology. Early in his medical career, he conducted important clinical and anthropometric studies among Japanese and Marshall Island children exposed to atomic radiation. These studies established standards for childhood growth and development still in use today. Dr. Sutow pioneered the multidisciplinary approach to childhood cancer by combining multidrug chemotherapy protocols with surgery and radiotherapy in the common childhood solid tumors. The textbook "Clinical Pediatric Oncology," of which he was the senior editor, served to define the discipline of pediatric oncology and educate a new era of oncologists in the curative treatment for childhood cancer. THE PAST AND PRESENT: The first edition of "Clinical Pediatric Oncology," published in 1973, demonstrated that only children with early-stage localized Hodgkin disease had a realistic opportunity for cure. Soon the use of combined-modality therapy consisting of low-dose, involved-field radiation plus multi-agent chemotherapy emerged, and made the goal of cure realistic for all patients. This approach is now universal. Today, the 5-year relative survival rate for American children with Hodgkin disease, who are under 14 years of age, is 94%, a dramatic and remarkable achievement. FUTURE: Management of children with Hodgkin disease now involves clinical staging and risk-adapted, combined-modality therapy. Clinical and translational research initiatives that hold promise for children with Hodgkin disease in the future include: use of the WHO Classification System combining morphologic and biologic criteria; noninvasive staging procedures with increased sensitivity and specificity; development of a useful prognostic index to define groups for risk-adapted therapy; high-dose therapy with stem cell transplantation; and novel therapies.
机译：先驱者：Wataru W. Sutow，1912年至1981年，是小儿肿瘤学领域一位杰出而举足轻重的领导者。在他的医学职业生涯初期，他对暴露于原子辐射的日本和马绍尔群岛儿童进行了重要的临床和人体测量研究。这些研究建立了当今仍在使用的儿童生长发育标准。 Sutow博士率先将多药化疗方案与儿童常见的实体瘤的手术和放疗相结合，开创了儿童癌症的多学科方法。他担任高级编辑的教科书《临床儿科肿瘤学》（Clinical Pediatric Oncology），旨在界定儿科肿瘤学的学科，并教育肿瘤学家对儿童癌症进行治疗的新时代。过去和现在：1973年出版的第一版“临床儿科肿瘤学”证明，只有患有早期局限性霍奇金病的儿童才有实际治愈的机会。不久，出现了由小剂量，累及场辐射加多药化疗组成的联合疗法，使所有患者的治疗目标变得现实。现在，这种方法是通用的。今天，美国14岁以下霍奇金病儿童的5年相对存活率达到94％，这是一项了不起的成就。未来：霍奇金病患儿的治疗现在涉及临床分期和适应风险的联合治疗。未来对霍奇金病患儿有希望的临床和转化研究计划包括：结合形态和生物学标准的WHO分类系统的使用;具有更高敏感性和特异性的无创分期程序;制定有用的预后指标，以定义风险适应疗法的组;大剂量治疗与干细胞移植;和新颖的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号